News 
Press Releases |
Company News |
Media Coverage |
Publications |
Presentations |
Conferences
ROANOKE, VA, Nov. 20, 2008 - Luna Innovations' emboli detection system known as EDAC® QUANTIFIER (Emboli Detection And Classification) is a noninvasive medical device that uses ultrasound technology to detect dangerous air bubbles, known as emboli, that can enter the blood circuit during medical procedures such as cardio-pulmonary bypass (CPB) surgery and cause potentially harmful effects. Cardiothoracic Surgeon Dr. Serdar Gunaydin has reported the results of incorporating the EDAC into his surgical practice in the November newsletter of AmSECT Today (American Society of ExtraCorporeal Technology), AmSECT is the professional association for perfusionists, the medical specialists who manage blood and blood circuitry during CPB, in the United States.
In Dr. Gunaydin's article titled "Air Handling and Cardiac Survey - EDAC QUANTIFIER Introduces New Concepts in Solving an Old Problem" he discusses his first-hand experiences with Luna's noninvasive medical device. Dr. Gunaydin comments on the air handling issues that led him to use the EDAC, how the device operates, his specific research using the instrument and the benefits he has derived from using EDAC during CPB procedures. "We believe data obtained via EDAC studies will change the future of cardiac surgery," said Dr. Gunaydin.
Numerous articles have linked microemboli to cognitive deficits in patients who have had a CPB procedure. To aid in reducing these cognitive deficits, Luna developed a noninvasive emboli monitor to detect and quantify gaseous microemboli in blood flowing through an extracorporeal circuit—the apparatus that carries a patient's blood outside of the body during medical procedures such as CPB, also known as the heart-lung machine. The EDAC alerts the perfusionist to microemboli in the circuit, thus triggering steps to reduce the number of emboli that ultimately reach the patient.
Dr. Gunaydin incorporated the EDAC in his surgical practice and detected gaseous microemboli in the extracorporeal circuit where he previously was not aware of its presence. "EDAC alerts significantly before studied monitoring technologies," noted Dr. Gunaydin. Early identification of microemboli is a critical first step in reducing emboli and its potentially negative effects. "To recommend interventions to reduce embolization, it is important to identify the source, quantity, and composition of microemboli detected during CPB," said Dr. Gunaydin. "We believe we have obtained revolutionary data of air embolism of significantly higher quantity than we expected, based on previous in vitro studies."
Dr. Gunaydin will continue his studies with the EDAC to include evaluation of air handling characteristics of minicircuits vs. conventional circuits, open vs. closed circuits, pulsatile vs. non-pusatile flow, comparison of characteristics of extracorporeal circuits from various manufacturers and the air generation in various medical procedures. His studies should be completed in February 2009.
Luna's EDAC® QUANTIFIER is a tool for the surgical team to collect near real-time data on the quantity and volume of gaseous emboli at multiple locations in extracorporeal circuits during such procedures. The device was introduced in 2006, is FDA cleared, CE marked and carries an ISO 13485 certification - an indication the EDAC holds a Quality Management Standard for Medical Devices. The article on the review of the EDAC can be downloaded here or see the full issue of AmSECT Today, at www.amsect.org.
About Luna Innovations:
Luna Innovations Incorporated develops and manufactures new-generation products for the healthcare, telecommunications, energy and defense markets. Our products are used to measure, monitor, protect and improve critical processes in the markets we serve. Through its disciplined commercialization business model, Luna has become a recognized leader in transitioning science to solutions. Luna is headquartered in Roanoke, Virginia.
Forward Looking Statements:
This release includes information that constitutes "forward-looking statements" made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995, including statements regarding the EDAC® device and the use and efficacy of the device and related data. Actual results may differ materially from the expectations expressed in such forward-looking statements as a result of various factors, including risks and uncertainties set forth in the company's periodic reports and other filings with the Securities and Exchange Commission. Such filings are available at the SEC's Web site at www.sec.gov, and at the company's Web site at www.lunainnovations.com. The statements made in this release are based on information available to the company as of the date of this release and Luna Innovations undertakes no obligation to update any of the forward-looking statements after the date of this release.
Name: Karin Clark
Title: Director, Marketing and Communications
Company: Luna Innovations
E-mail:
Phone: 1.540.769.8400
Name: John Baldissera
Title: BPC Financial Marketing
E-mail:
Phone: 1.800.368.1217
Press Releases |
Company News |
Media Coverage |
Publications |
Presentations |
Conferences
Company News
Luna's Emboli Detection System Reviewed in Leading Medical Publication
Cardiothoracic surgeon reports on benefits of Luna's EDAC® QUANTIFIER in American Society of Extracorporeal Technology NewsletterLuna Innovations' EDAC® QUANTIFIER, an FDA-cleared emboli detection system that non-invasively monitors for emboli during invasive medical procedures such as cardiopulmonary bypass surgery is featured in the November issue of AmSECT Today. In the article, Dr. Serdar Gunaydin discusses the benefits of using EDAC® during cardiopulmonary bypass procedures.
Download High Resolution Image (1.4 MB)
Download High Resolution Image (1.4 MB)
In Dr. Gunaydin's article titled "Air Handling and Cardiac Survey - EDAC QUANTIFIER Introduces New Concepts in Solving an Old Problem" he discusses his first-hand experiences with Luna's noninvasive medical device. Dr. Gunaydin comments on the air handling issues that led him to use the EDAC, how the device operates, his specific research using the instrument and the benefits he has derived from using EDAC during CPB procedures. "We believe data obtained via EDAC studies will change the future of cardiac surgery," said Dr. Gunaydin.
Numerous articles have linked microemboli to cognitive deficits in patients who have had a CPB procedure. To aid in reducing these cognitive deficits, Luna developed a noninvasive emboli monitor to detect and quantify gaseous microemboli in blood flowing through an extracorporeal circuit—the apparatus that carries a patient's blood outside of the body during medical procedures such as CPB, also known as the heart-lung machine. The EDAC alerts the perfusionist to microemboli in the circuit, thus triggering steps to reduce the number of emboli that ultimately reach the patient.
Dr. Gunaydin incorporated the EDAC in his surgical practice and detected gaseous microemboli in the extracorporeal circuit where he previously was not aware of its presence. "EDAC alerts significantly before studied monitoring technologies," noted Dr. Gunaydin. Early identification of microemboli is a critical first step in reducing emboli and its potentially negative effects. "To recommend interventions to reduce embolization, it is important to identify the source, quantity, and composition of microemboli detected during CPB," said Dr. Gunaydin. "We believe we have obtained revolutionary data of air embolism of significantly higher quantity than we expected, based on previous in vitro studies."
Dr. Gunaydin will continue his studies with the EDAC to include evaluation of air handling characteristics of minicircuits vs. conventional circuits, open vs. closed circuits, pulsatile vs. non-pusatile flow, comparison of characteristics of extracorporeal circuits from various manufacturers and the air generation in various medical procedures. His studies should be completed in February 2009.
Luna's EDAC® QUANTIFIER is a tool for the surgical team to collect near real-time data on the quantity and volume of gaseous emboli at multiple locations in extracorporeal circuits during such procedures. The device was introduced in 2006, is FDA cleared, CE marked and carries an ISO 13485 certification - an indication the EDAC holds a Quality Management Standard for Medical Devices. The article on the review of the EDAC can be downloaded here or see the full issue of AmSECT Today, at www.amsect.org.
About Luna Innovations:
Luna Innovations Incorporated develops and manufactures new-generation products for the healthcare, telecommunications, energy and defense markets. Our products are used to measure, monitor, protect and improve critical processes in the markets we serve. Through its disciplined commercialization business model, Luna has become a recognized leader in transitioning science to solutions. Luna is headquartered in Roanoke, Virginia.
Forward Looking Statements:
This release includes information that constitutes "forward-looking statements" made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995, including statements regarding the EDAC® device and the use and efficacy of the device and related data. Actual results may differ materially from the expectations expressed in such forward-looking statements as a result of various factors, including risks and uncertainties set forth in the company's periodic reports and other filings with the Securities and Exchange Commission. Such filings are available at the SEC's Web site at www.sec.gov, and at the company's Web site at www.lunainnovations.com. The statements made in this release are based on information available to the company as of the date of this release and Luna Innovations undertakes no obligation to update any of the forward-looking statements after the date of this release.
Media Contact Information
Name: Karin Clark
Title: Director, Marketing and Communications
Company: Luna Innovations
E-mail:
Phone: 1.540.769.8400
Investor Contact
Name: John Baldissera
Title: BPC Financial Marketing
E-mail:
Phone: 1.800.368.1217
